Buck Wealth Strategies’s Crinetics Pharmaceuticals CRNX Stock Holding History

Buck Wealth Strategies’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$299	Buy	+8	New	+$297	﹤0.01%	1056

Other funds holding CRNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Universal-Beteiligungs- und Servicegesellschaft Frankfurt Am Main, Germany $65.4B AUM 39.83% 1-Year Est. Return

BSA

Braun Stacey Associates New York $3.53B AUM 63.32% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Buck Wealth Strategies's CRNX Position: Q2 2026 in Review

Buck Wealth Strategies opened a new position in Crinetics Pharmaceuticals (CRNX) in Q2 2026: 8 shares worth $299. The stake represents ﹤0.01% of the portfolio and ranks #1056 among its holdings.

104 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

Buck Wealth Strategies held 8 shares of Crinetics Pharmaceuticals worth $299 as of Q2 2026.
Crinetics Pharmaceuticals was a new Buck Wealth Strategies position in Q2 2026.
Crinetics Pharmaceuticals made up ﹤0.01% of Buck Wealth Strategies's portfolio in Q2 2026, its #1056 holding.
104 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Buck Wealth Strategies's 13F filing for Q2 2026, filed 30 Jul 2026.